ASMS 2023: A Look at the Tuesday Morning Oral Session on Drug Metabolism and Pharmacokinetics

From 8:30–10:30 a.m., there was an oral session titled “Drug Metabolism and Pharmacokinetics” which took place in General Assembly B. The session, chaired and presided over by Josh Yu of Gilead, included six talks focusing on drug identification and quantification using various mass spectrometry techniques.

First, at 8:30 a.m., Ismael Zamora of Lead Molecular Design, S.L., in Sant Cugat del Vallès, Spain discussed the favorable performance of automated high-resolution mass spectrometry (HRMS) as opposed to a triple-quadrupole mass spectrometer (QqQ) in data processing for drug quantification studies.

Next at 8:50 a.m., Rahul Baghla of SCIEX in Redwood City, California, USA gave a talk on how diagnostic fragments from orthogonal tandem mass spectrometry (MS/MS) data lend more confidence to the characterization and identification of glucuronide metabolites.

Following at 9:10 a.m., Xue Dong of Amgen, Inc. in South San Francisco, California, USA took a look at mitochondrial Amidoxime Reducing Component 1 (mARC1), a molybdenum-containing reductive enzyme, in the liver of different species using a reagent free-automatic high pH (RF-auto HpH) fractionation enrichment prior to analysis by liquid chromatography coupled to mass spectrometry (LC–MS).

At 9:30 a.m., Ralf Laux of Boehringer Ingelheim in Biberach, Germany presented his company’s findings in the use of accelerator mass spectrometry (AMS) combined with a carbon dioxide gas inlet interface and microtracer trial designs for human absorption, distribution, metabolism, and excretion for ultrahigh sensitive analysis of 14C labeled compounds.

The penultimate talk of the session, given at 9:50 a.m. by Rutali Brahme of Northeastern University in Boston, Massachusetts, USA, centered on covalent drug discovery including pharmacokinetics and pharmacodynamics, tissue distribution, route of administration, dose estimation, and efficacy through intact protein mass analysis.

Closing the oral session at 10:10 a.m. was Xue Wang of the AbbVie Bioresearch Center in Worcester, Massachusetts, USA, who talked about the robust characterization of complex transitional in vitro models for oral prodrugs using quantitative proteomics.